Sensus Healthcare (Sensus Healthcare) Capex-to-Revenue : 0.02 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Sensus Healthcare Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Sensus Healthcare's Capital Expenditure for the three months ended in Mar. 2024 was $-0.23 Mil. Its Revenue for the three months ended in Mar. 2024 was $10.66 Mil.

Hence, Sensus Healthcare's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.02.

Sensus Healthcare Capex-to-Revenue Historical Data

The historical data trend for Sensus Healthcare's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensus Healthcare Capex-to-Revenue Chart

Sensus Healthcare Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

Get a 7-Day Free Trial

0.02

0.04

0.01

Sensus Healthcare Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Revenue	Get a 7-Day Free Trial															0.06	0.01	-	-	0.02

Competitive Comparison of Sensus Healthcare's Capex-to-Revenue

For the Medical Devices subindustry, Sensus Healthcare's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sensus Healthcare's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sensus Healthcare's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sensus Healthcare's Capex-to-Revenue falls into.

Sensus Healthcare Capex-to-Revenue Calculation

Sensus Healthcare's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.229)	/	24.405
	=	0.01

Sensus Healthcare's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-0.233)	/	10.663
	=	0.02

Sensus Healthcare (NAS:SRTS) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Sensus Healthcare Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sensus Healthcare's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sensus Healthcare (Sensus Healthcare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sensus Healthcare Inc (NAS:SRTS) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

5TX:Germany

Address

851 Broken Sound Parkway, NW, Suite 215, Boca Raton, FL, USA, 33487

Website

https://www.sensushealthcare.com

Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating skin cancers including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.

Executives

Joseph C Sardano	director, officer: Chief Executive Officer	851 BROKEN SOUND PARKWAY NW, STE. 215, BOCA RATON FL 33487
Michael Sardano	officer: GENERAL COUNSEL	851 BROKEN SOUND PARKWAY NW STE. 215, BOCA RATON FL 33487
John Heinrich	director	851 BROKEN SOUND PARKWAY NW, STE. 215, BOCA RATON FL 33487
Samuel O'rear	director	851 BROKEN SOUND PARKWAY NW, STE. 215, BOCA RATON FL 33487
Magdalena Martinez	officer: Chief Operating Officer	851 BROKEN SOUND PARKWAY NW #215, BOCA RATON FL 33487
Emiliano Sosa	officer: Chief Technology Officer	851 BROKEN SOUND PARKWAY NW #215, BOCA RATON FL 33487
William H Mccall	director	851 BROKEN SOUND PARKWAY NW STE. 215, BOCA RATON FL 33487
Nicolas Soro	officer: Chief Operating Officer	851 BROKEN SOUND PARKWAY NW STE 215, BOCA RATON FL 33487
Javier Rampolla	officer: Chief Financial Officer	851 BROKEN SOUND PARKWAY NW STE 215, BOCA RATON FL 33487
Stephen Brad Cohen	officer: EXECUTIVE VICE PRESIDENT	851 BROKEN SOUND PARKWAY NW, STE. 215, BOCA RATON FL 33487
Megan Cornish	director	851 BROKEN SOUND PARKWAY NW #215, BOCA RATON FL 33487
Yonatan Vainer	officer: Chief Technology Officer	851 BROKEN SOUND PARKWAY NW #215, BOCA RATON FL 33487
Russ Price	officer: Chief Technology Officer	851 BROKEN SOUND PARKWAY NW STE 215, BOCA RATON FL 33487
Kalman Fishman	officer: CHIEF TECHNOLOGY OFFICER	851 BROKEN SOUND PARKWAY NW #215, BOCA RATON FL 33487
Richard Golin	officer: EXECUTIVE VICE PRESIDENT	851 BROKEN SOUND PARKWAY NW, STE. 215, BOCA RATON FL 33487